Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas the thyroid

被引:56
作者
Hunt, JL [1 ]
Tometsko, M
LiVolsi, VA
Swalsky, PO
Finkelstein, SD
Barnes, EL
机构
[1] Univ Pittsburgh, Ctr Med, Dept Pathol, Pittsburgh, PA 15213 USA
[2] Univ Penn, Hlth Syst, Dept Pathol, Philadelphia, PA 19104 USA
关键词
anaplastic carcinoma; papillary carcinoma; Hurthle cell carcinoma; loss of heterozygosity;
D O I
10.1097/00000478-200312000-00009
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
Anaplastic thyroid cancer is a rare but nearly universally fatal tumor. Epidemiologic data suggest that many anaplastic thyroid carcinomas arise from transformation of preexisting or coexisting well-differentiated thyroid carcinomas. At the molecular level, the mutations responsible for the anaplastic transformation are incompletely understood, although the mutational events are thought to involve tumor suppressor genes. To examine transformation from a well-differentiated thyroid carcinoma to anaplastic carcinoma, we studied coexisting well-differentiated (Hurthle cell and papillary carcinoma) and anaplastic tumors with a molecular genotyping panel of tumor suppressor genes associated with thyroid neoplasia. The patterns of allelic loss in our results showed that the majority of cases have a core of conserved mutations in the two morphologically distinct areas and substantial increases in mutation rates in the anaplastic components.
引用
收藏
页码:1559 / 1564
页数:6
相关论文
共 36 条
[1]
Multistep carcinogenesis in anaplastic thyroid carcinoma: A case report [J].
Asakawa, H ;
Kobayashi, T .
PATHOLOGY, 2002, 34 (01) :94-97
[2]
Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma [J].
Baloch, ZW ;
LiVolsi, VA .
THYROID, 2001, 11 (07) :637-645
[3]
BRONNER MP, 1991, MODERN PATHOL, V4, P637
[4]
Our AMES is true: How an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer [J].
Cady, B .
AMERICAN JOURNAL OF SURGERY, 1997, 174 (05) :462-468
[5]
Dean D S, 2000, Cancer Control, V7, P229
[6]
Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer [J].
Frisk, T ;
Foukakis, T ;
Dwight, T ;
Lundberg, J ;
Höög, A ;
Wallin, G ;
Eng, C ;
Zedenius, J ;
Larsson, C .
GENES CHROMOSOMES & CANCER, 2002, 35 (01) :74-80
[7]
NUCLEAR-DNA IN ANAPLASTIC THYROID-CARCINOMA WITH A DIFFERENTIATED COMPONENT [J].
GALERADAVIDSON, H ;
BIBBO, M ;
DYTCH, HE ;
GONZALEZCAMPORA, R ;
FERNANDEZ, A ;
WIED, GL .
HISTOPATHOLOGY, 1987, 11 (07) :715-722
[8]
Encapsulated anaplastic thyroid carcinoma with three-year disease-free survival [J].
Guimaraes, L ;
Meneses, A ;
Carrara, W ;
Kefalás, A .
PATHOLOGY RESEARCH AND PRACTICE, 2000, 196 (12) :867-870
[9]
Anaplastic thyroid carcinoma. [J].
Haigh P.I. .
Current Treatment Options in Oncology, 2000, 1 (4) :353-357
[10]
Haigh PI, 2001, CANCER-AM CANCER SOC, V91, P2335, DOI 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.3.CO